Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in Neovascular Glaucoma

Cutaneous and Ocular Toxicology

Volumn 31, Issue 2, 2012, Pages 124-127

  Kocak Altintas, Ayse Gul ^a   Arifoglu, Hasan Basri ^b   Tutar, Esen ^a   Koklu, Gultekin ^a   Ozcan, Pehmen Yasin ^a  

^a Ophthalmology Department   (Turkey)

^b Rize Devlet Hastanesi   (Turkey)

Author keywords

bevacizumab; glaucoma drainage devices; Iris neovascularization; neovascular glaucoma

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ANTERIOR EYE SEGMENT; ARTICLE; CLINICAL ARTICLE; EYE PHOTOGRAPHY; FEMALE; FILTERING OPERATION; FOLLOW UP; GLAUCOMA DRAINAGE IMPLANT; HUMAN; INTRAOCULAR PRESSURE; IRIS RUBEOSIS; MALE; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); POSTERIOR EYE CHAMBER; PROSPECTIVE STUDY; REMISSION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS; IRITIS; MALE; MIDDLE AGED; SUTURE TECHNIQUES;

EID: 84862062222     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2011.621917     Document Type: Article

References (13)

1. Qureshi K, Kashani S, Kelly SP. Intracameral bevacizumab for rubeotic glaucoma secondary to retinal vein occlusion. Int Ophthalmol 2008;29:537-539.
2. Duch S, Buchacra O, Milla E, Andreu D, Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: A pilot study in 6 patients. J Glaucoma 2009;18:140-143.
3. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160.
4. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571-80, 1580.e1.
5. Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol 2008;28:59-61.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
7. Teich SA, Walsh JB. A grading system for iris neovascularization. Prognostic implications for treatment. Ophthalmology 1981;88: 1102-1106.
8. Meyer CH, Mennel S, Eter N. [Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application]. Ophthalmologe 2007;104:952-957.
9. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
10. Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008;18:255-262.
11. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 2009;19:435-441.
12. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26:977-982.
13. Kernt M, Welge-Lüssen U, Yu A, Neubauer AS, Kampik A. [Bevacizumab is not toxic to human anterior- and posteriorsegment cultured cells]. Ophthalmologe 2007;104:965-971.